Antibiotic Stewardship to Prevent Early Sepsis in Preterm Infants
NCT06930911 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 711
Last updated 2025-04-16
Summary
Early onset sepsis (EOS) occurs in newborns within the first 72 hours of life, and is rare, about 0.8 cases per 1000 births (1). It is more frequent in premature infants and potentially more severe (as much as 75% of deaths has been reported in extreme premature infants (1)). Infection is considered as confirmed when blood or cerebral fluid cultures detect a pathogen (1). It is considered probable when cultures are negative, but there are clinical (fever, hemodynamic failure, severe respiratory condition) and biological (inflammatory markers) signs suggestive of infection. In 2017, French recommendations for prevention of EOS in term and near-term infants has been proposed. However, to date, there are no recommendations for the population of premature newborns, and there are discrepancies in practices antibiotic stewardship to prevent early sepsis in infants born before 35 weeks. Preterm infants are more exposed to EOS than infants born closer to term. The incidence is inversely proportional to gestational age, reaching 32 cases per 1000 births in infants born between 22 and 24 weeks. Infection is a major cause of mortality and morbidity in premature newborns, because of the immaturity of their immune system. The death rate reach 50% in infants born between 22 and 28 weeks. For these reasons, probabilistic antibiotic therapy is prescribed at admission in Neonatology in 35 to 50% of very premature babies. But it appears that the prescription of antibiotics is not correlated with the incidence of EOS, with overuse of antibiotics, related to the fear of infection in these fragile patients. However, exposure to antibiotics induces gut dysbiosis, which is the main risk factor of necrotizing enterocolitis, a potentially severe disease occurring specifically in preterm infants. It is therefore important to optimize antibiotic stewardship in the days following birth, to improve the quality of care. To this end, we shall analyse antibiotic prescription practices and the rate of EOS in premature newborns hospitalized in a tertiary care unit at the Croix Rousse university hospital.
Conditions
- Prematurity, Infections
Interventions
- BIOLOGICAL
-
Antibiotic therapy
Evaluating antibiotic exposure in premature infants before 35 weeks in a tertiary care neonatal unit
Sponsors & Collaborators
-
Hospices Civils de Lyon
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-02-01
- Primary Completion
- 2025-05-01
- Completion
- 2025-05-01
Countries
- France
Study Locations
More Related Trials
-
Efficacy And Safety Of Short Course Antibiotic Therapy In Preterm Neonates With Early Onset Sepsis
NCT06197269 ·Status: COMPLETED ·Phase: NA
-
Staphylococcus Haemolyticus in the Neonatal Intensive Care Unit of CHSD in 2023: Analysis and Trends
NCT07013864 ·Status: COMPLETED
-
Promoting Optimal Treatment Choices in Neonates With Suspected Early-Onset Sepsis
NCT06845332 ·Status: RECRUITING
-
Resistant Bacteria in Children in France
NCT06036628 ·Status: COMPLETED
-
Management of Early Onset Neonatal Septicaemia: Selection of Optimal Antibacterial Regimen for Empiric Treatment
NCT00487019 ·Status: COMPLETED
-
Bacillus Cereus Invasive Infections in Preterm Neonates Hospitalized in French Hospitals
NCT06973174 ·Status: RECRUITING
-
NICU Antibiotics and Outcomes Trial
NCT03997266 ·Status: COMPLETED ·Phase: PHASE4
-
Role of Antibiotics in Preventing Infection in Babies Born Through Meconium Stained Liquor
NCT01290003 ·Status: COMPLETED ·Phase: NA
-
A Pilot Randomized Controlled Trial for Antibiotic Exposure in Neonatal Sepsis Using Neutrophil CD64
NCT01825421 ·Status: WITHDRAWN ·Phase: NA
-
Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates
NCT00873327 ·Status: COMPLETED ·Phase: PHASE1
-
Ceftriaxone and Jaundice in Neonates
NCT03133637 ·Status: COMPLETED
-
An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates
NCT00850122 ·Status: COMPLETED ·Phase: PHASE1
-
Multi-resistant and Spore-forming Bacteria in a Neonatal Intensive Care Unit
NCT06391463 ·Status: ENROLLING_BY_INVITATION
-
Efficacy Study of Community-Based Treatment of Serious Bacterial Infections in Young Infants
NCT00189384 ·Status: UNKNOWN ·Phase: PHASE3
-
Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes
NCT02819570 ·Status: UNKNOWN ·Phase: PHASE4
-
Infant Antibiotic Resistance and Implications for Therapeutic Decision-making
NCT01781182 ·Status: COMPLETED
-
Microbiology, Antimicrobial Resistance and Outcomes of Neonatal Sepsis in China
NCT05089760 ·Status: UNKNOWN
-
An Open Label Study to Describe the Pharmacokinetics of Daptomycin in Infants
NCT00942149 ·Status: COMPLETED ·Phase: PHASE1
-
Neonatal Vancomycin Trial
NCT02790996 ·Status: TERMINATED ·Phase: PHASE2
-
Personalized Optimization of Antibiotic Therapy in Pulmonary Sepsis Critically Ill Patients Through Application of Rapid Microbiological Diagnostic Technologies and Pharmacokinetic/Pharmacodynamic Modelling
NCT06956053 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days With Clinical or Confirmed Late-onset Sepsis
NCT01551394 ·Status: COMPLETED ·Phase: PHASE3
-
Population Pharmacokinetics of Amikacin in Neonates
NCT04867135 ·Status: COMPLETED
-
SEPSIS: L. Plantarum Trial
NCT05180201 ·Status: COMPLETED ·Phase: PHASE2
-
Improving Dosing of Vancomycin in Young Infants With Infections
NCT04044703 ·Status: COMPLETED ·Phase: PHASE4
-
Neonatal Bacterial Colonization Study
NCT03896893 ·Status: UNKNOWN ·Phase: NA